drugset / Trial / NCT00310856

Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)

NCT00310856

Phase 2 Completed 175 enrolled Novartis Vaccines
RandomizedParallel-groupOpen-labelPrevention

Summary

To assess the immunogenicity of Novartis (formerly Chiron) Meningococcal ACWY conjugate vaccine (MenACWY) when administered as a two-dose schedule at 6 and 12 months of age.

Timeline

Start
2005-06
Primary completion
2006-11
Completion
2006-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Menjugate Vaccine 0.5 ml Intramuscular
Subject Menveo Vaccine 0.5 ml Intramuscular
Background DTaP-Hib-IPV Vaccine
Background MMR Unknown
Background PC7 Vaccine 0.5 ml Intramuscular
Background Varicella Vaccine